alexa

GET THE APP

LilrB2 Inhibition Unlocks A New Hope In Alzheimer’s Disease Therapy | 39095
ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences

2nd International Conference on Biotechnology and Healthcare

Auckland, New Zealand

6th International Conference on Vaccines and Immunology

Geneva, Switzerland

3rd European Congress on Virology

Geneva, Switzerland
Google scholar citation report
Citations : 1600

Journal of Biotechnology & Biomaterials received 1600 citations as per google scholar report

Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • ResearchBible
  • China National Knowledge Infrastructure (CNKI)
  • Access to Global Online Research in Agriculture (AGORA)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

LilrB2 inhibition unlocks a new hope in Alzheimer’s disease therapy

6th World Congress on Biotechnology

Ruchi Jakhmola Mani and Deepshikha Pande Katare

Amity University, India

Posters-Accepted Abstracts: J Biotechnol Biomater

DOI: 10.4172/2155-952X.C1.044

Abstract
Alzheimer’s disease (AD) is a progressive and irreversible brain illness which gradually abolishes one’s cognitive skills and rational thinking. The two major hallmarks of AD are the extracellular deposition of the Amyloid-beta (Aβ) fragments resulting in plaques and intracellular accumulation of neurofibrillary tangles of tau protein. LilrB2 is a recently discovered receptor for Aβ and is responsible for the increased accumulation and reduced clearance of Aβ from the brain. Therefore, LilrB2 inhibition can suppress the aggregation of Aβ plaques. In this study we have computationally modeled the 3D-structure of four isoforms of LilrB2. Structures were later super-imposed to calculate their RMSD and individually docked with Aβ to examine the most appropriate isoform for inhibition. Virtual screening of best isoform reports some potential compounds which can inhibit LilrB2. Studies are underway to validate the identified compounds in the animal model of AD.
Biography

Ruchi Jakhmola Mani is a PhD scholar and Faculty of Bioinformatics at Amity Institute of Biotechnology, Amity University, India. She has completed her Master’s degree in Bioinformatics from Panjab University, Chandigarh. She has six years of teaching experience with some peer-reviewed publications. At present, she is working with zebrafish model of Alzheimer’s disease.

Email: [email protected]

Top